Findings from Chengdu Second People's Hospital Broaden Understanding of Chronic Obstructive Pulmonary Disease [Dual Bronchodilator Versus Inhaled Corticosteroid/long-acting Beta(2)-agonist In Patients With Chronic Obstructive Pulmonary Disease: ...]

摘要

2021 MAY 05 (NewsRx) - By a News Reporter-Staff News Editor at Disease Prevention Daily - New research on Lung Diseases and Conditions - Chronic Obstructive Pulmonary Disease is the subject of a report. According to news reporting from Chengdu, People's Republic of China, by NewsRx journalists, research stated, "Long-acting muscarinic antagonist/long-acting beta 2-agonist (LAMA/LABA, also known as dual bronchodilator) and inhaled corticosteroid/LABA (ICS/ LABA) are the cornerstone of maintenance treatment for stable chronic obstructive pulmonary disease (COPD) patients. We aimed to comprehensively compare the efficacy and safety of the two maintenance treatment in COPD patients."